Taligen Therapeutics Adds $10 Mil. Tranche, Reveals Broad Patent
The developer of therapies that act on the complement system expects to partner in ophthalmology while keeping its orphan disease program in-house.
The developer of therapies that act on the complement system expects to partner in ophthalmology while keeping its orphan disease program in-house.